KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Treasury Shares: 2015-2018

Historic Treasury Shares for BeOne Medicines (ONC) over the last 1 years, with Dec 2018 value amounting to $14.1 million.

  • BeOne Medicines' Treasury Shares rose 859.71% to $14.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $14.1 million, marking a year-over-year increase of 859.71%. This contributed to the annual value of $14.1 million for FY2018, which is 859.71% up from last year.
  • According to the latest figures from Q4 2018, BeOne Medicines' Treasury Shares is $14.1 million, which was up 33.97% from $10.5 million recorded in Q2 2018.
  • Over the past 5 years, BeOne Medicines' Treasury Shares peaked at $14.1 million during Q4 2018, and registered a low of $44,445 during Q4 2015.
  • In the last 3 years, BeOne Medicines' Treasury Shares had a median value of $2.8 million in 2017 and averaged $5.4 million.
  • Data for BeOne Medicines' Treasury Shares shows a peak YoY spiked of 2,318.72% (in 2016) over the last 5 years.
  • Over the past 4 years, BeOne Medicines' Treasury Shares (Quarterly) stood at $44,445 in 2015, then soared by 2,318.72% to $1.1 million in 2016, then soared by 36.69% to $1.5 million in 2017, then skyrocketed by 859.71% to $14.1 million in 2018.
  • Its last three reported values are $14.1 million in Q4 2018, $10.5 million for Q2 2018, and $4.1 million during Q1 2018.